News >

IFN-Gamma Signature Not Linked to Durvalumab/Tremelimumab Benefit in Gastric Cancer

Brandon Scalea
Published: Monday, Apr 22, 2019

eoffrey Y. Ku, MD

Geoffrey Y. Ku, MD

Although prospective screening with an RNA-based interferon (IFN)-γ gene expression signature proved feasible for selecting patients with gastric cancer who would most benefit from the combination of durvalumab (Imfinzi) and tremelimumab, use of this signature failed to lead to a significant improvement in clinical outcomes, said Geoffrey Y. Ku, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x